Creative Medical Technology Holdings (CELZ) Amortizatization of Intangibles (2017 - 2025)
Creative Medical Technology Holdings (CELZ) posted quarterly Amortizatization of Intangibles of -$33162.0 for Q4 2025, up 3.75% year-over-year from -$31962.5 in Q4 2024, and up 3.75% quarter-over-quarter from -$34455.0 in Q4 2024.
Creative Medical Technology Holdings (CELZ) Amortizatization of Intangibles (2017 - 2025) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Amortizatization of Intangibles for 7 consecutive years, with -$33162.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Amortizatization of Intangibles rose 3.75% year-over-year to -$33162.0; the TTM figure through Dec 2025 stood at -$67617.0 (down 96.25% YoY), while the FY2025 annual figure was $1584.0, changed N/A from the prior year.
- Amortizatization of Intangibles rose to -$33162.0 in Q4 2025 per CELZ's latest filing, from -$34455.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $2.4 million in Q4 2021 and bottomed at -$34455.0 in Q4 2024.
- Historically, Amortizatization of Intangibles has averaged $681705.5 across 3 years, with a median of $225807.0 in 2021.
- On a YoY basis, Amortizatization of Intangibles climbed as much as 1272.51% in 2021 and fell as far as 20.22% in 2021.
- Creative Medical Technology Holdings' Amortizatization of Intangibles stood at $2.4 million in 2021, then sank by 101.43% to -$34455.0 in 2024, then gained by 3.75% to -$33162.0 in 2025.
- Business Quant data shows CELZ's Amortizatization of Intangibles at -$33162.0 in Q4 2025, -$34455.0 in Q4 2024, and $2.4 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Creative Medical Technology Holdings | 1.88 Mn | 1.88 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -33,162.00 |
| Dec 31, 2025 | -33,162.00 |
| Dec 31, 2024 | -34,455.00 |
| Dec 31, 2024 | -34,455.00 |
| Dec 31, 2021 | 2.40 Mn |
| Dec 31, 2021 | 2.40 Mn |
| Sep 30, 2021 | 1.30 Mn |
| Sep 30, 2021 | 1.30 Mn |
| Jun 30, 2021 | 220,382.00 |
| Jun 30, 2021 | 220,382.00 |
| Mar 31, 2021 | 231,232.00 |
| Mar 31, 2021 | 231,232.00 |
| Dec 31, 2020 | 175,062.00 |
| Dec 31, 2020 | 175,062.00 |
| Sep 30, 2020 | 260,982.00 |
| Sep 30, 2020 | 260,982.00 |
| Jun 30, 2020 | 254,091.00 |
| Jun 30, 2020 | 254,091.00 |
| Mar 31, 2020 | 289,825.00 |
| Mar 31, 2020 | 289,825.00 |